elvitegravir

Genvoya (elvitegravir) is the first single tablet for the treatment of AIDS. Its ingredients include Elvitegravir/cobicistat/emtricitabine/tenofovir alafenadmide.

[Dosage Form]

This product is a capsule, packed with 30 tablets, each package contains 150mg/150mg/200mg/10mg of the above ingredients.

[Usage and Dosage]

Adults and adolescents aged 12 years and above and weighing at least 35kg

Take one tablet once a day with food.

If the patient misses a dose of Icoin Protein Tablets within 18 hours of the normal medication time, the patient should take another dose with food as soon as possible and resume the normal medication time.

If the patient misses a dose of Icoinib for more than 18 hours, the patient should not take the missed dose and only resume the normal medication time.

If the patient vomits within 1 hour after taking the Icoin tablet, another tablet should be taken.

Elderly

For elderly patients, there is no need to adjust the dose of Icoin Protein Tablets.

Renal function impairment

For adults or adolescents (at least 12 years old and weighing at least 35kg) whose creatinine clearance (CrCl) is estimated to be 30 mL/min, there is no need to adjust the dose of Iconin.

Patients with CrC1 estimates <30 mL/min should not be treated with Icoin, as there are limited data available on the use of Icoin in this population.

For patients whose CrCI value drops to less than 30mL/min during treatment, Icoinpratin tablets should be discontinued.

Hepatic Impairment

No dose adjustment of Icoin is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.

Icoinpratin Tablets have not been studied in patients with severe hepatic impairment (Child-Pugh class C); therefore, Icoinpretitan Tablets are not recommended for use in patients with severe hepatic impairment.

Pediatric Population

The safety and efficacy of Aikanbi Tablets have not been established in children under 12 years of age or weighing <35kg. No data available yet.

Dosage Method

Oral, once a day with food. Do not chew, crush or break for consumption.

[Indications]

Genvoya (elvitegravir) is particularly suitable for patients who have never received anti-HIV treatment, or whose HIV virus has been controlled at 50/ml within six months, and who have not developed resistance to the active ingredients of the drug.